Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma

Camptothecin (CPT), a potent inhibitor of topoisomerase I and HIF-1α, failed to demonstrate utility as an anti-cancer agent in early clinical trial investigations, primarily due to limited clinical activity and significant toxicity attributable to unfavorable physicochemical properties (e.g. low pla...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pharm Biomed Anal
Main Authors: Schmidt, Keith T., Peer, Cody J., Huitema, Alwin D. R., Williams, Monique D., Wroblewski, Susan, Schellens, Jan H. M., Madan, Ravi A., Figg, William D.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7068816/
https://ncbi.nlm.nih.gov/pubmed/31927166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2019.113073
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares